LMP744 drug for returning glioblastoma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have glioblastoma that has returned after treatment
- You are able to have brain surgery (biopsy or removal)
- You are willing to use effective birth control during the study
- You generally feel well enough to care for yourself (Karnofsky score over 60)
- You can have an MRI scan of your brain
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
This early study looks at a treatment plan (including resection/surgery and an added medicine) for glioblastoma that has come back after standard therapy. The goal is to see how well it controls tumor growth and whether it is tolerable.
This trial tests how well different doses of a new drug, BI 764532, are tolerated by people with a specific type of brain tumor (glioma) that has not responded to standard treatments. The drug targets a protein on the tumor cells, which may help slow tumor growth.
This trial tests a new drug (KH617) for people whose glioblastoma has returned after the first round of standard treatment. The drug is hoped to slow or stop the tumor's growth. You must have a specific genetic marker (MGMT unmethylated) and be in fairly good health to join.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.